Another approval last week in this drug class. SIRNA drug approval
Merck bought, floundered in R&D, and finally sold SIRNA to Alnylam at a huge loss (bought at 1.1 billion and sold for 175 million). Frustrating. My butthole is still hurting from it.
Merck is still 0 for whatever finding new biotech drugs. Dick Clark, Peter Kim, Ken Frazier & Roger Perlmutter have f*cked up small molecule R&D labs in the process. So where are all the large molecules flowing from R&D? Luckily stumbled onto Keytruda. Big win for Roger.
Rosetta, purchased for $620 million in 2001.
Glycofi, bought for $400 million in 2006.
Cubist $9.5 billion
Antelliq $2.4 billion
Themis (undisclosed)
NGM Biopharmaceuticals $450 million and counting
Immune Design $300 million
VelosBio $2.75 billion
ArQule $2.75 billion
Peloton $2.2 billion
OncoImmune $425 million
to name a few, $21 billion and counting
Plus $41 billion for SP. Was it worth Keytruda? Maybe
Merck bought, floundered in R&D, and finally sold SIRNA to Alnylam at a huge loss (bought at 1.1 billion and sold for 175 million). Frustrating. My butthole is still hurting from it.
Merck is still 0 for whatever finding new biotech drugs. Dick Clark, Peter Kim, Ken Frazier & Roger Perlmutter have f*cked up small molecule R&D labs in the process. So where are all the large molecules flowing from R&D? Luckily stumbled onto Keytruda. Big win for Roger.
Rosetta, purchased for $620 million in 2001.
Glycofi, bought for $400 million in 2006.
Cubist $9.5 billion
Antelliq $2.4 billion
Themis (undisclosed)
NGM Biopharmaceuticals $450 million and counting
Immune Design $300 million
VelosBio $2.75 billion
ArQule $2.75 billion
Peloton $2.2 billion
OncoImmune $425 million
to name a few, $21 billion and counting
Plus $41 billion for SP. Was it worth Keytruda? Maybe